Table 2.

Imaging features and interreader agreement

Imaging features	SR 1			SR 2			JR 1			JR 2			k SR	k JR	k AR
	HCC	Non-HCC	p	HCC	Non-HCC	p	HCC	Non-HCC	p	HCC	Non-HCC	p
Arterial phase hyperenhancement (APHE)	46 (90%)	43 (86%)	0.439	43 (84%)	35 (70%)	0.134	47 (92%)	42 (84%)	0.159	50 (98%)	48 (96%)	0.745	0.45	0.29	0.35
Washout	39 (76%)	5 (10%)	<0.001	39 (76%)	13 (25%)	<0.001	40 (78%)	11 (22%)	<0.001	39 (76%)	18 (35%)	<0.001	0.65	0.29	0.50
Capsule	36 (71%)	25 (49%)	0.043	31 (61%)	10 (20%)	<0.001	33 (65%)	10 (20%)	<0.001	28 (55%)	8 (16%)	<0.001	0.43	0.53	0.41
Tumor in vein	5 (10%)	8 (16%)	0.374	16 (32%)	13 (26%)	0.738	3 (6%)	2 (4%)	0.617	1 (2%)	0 (0%)	0.999	0.35	0.37	0.33
Diameter Mean (±SD)	5.9 (4)	5.3 (2.3)	0.357	5.9 (4.2)	5.3 (2.4)	0.385	5.9 (4)	5.3 (2.4)	0.334	5.6 (3.9)	5.1 (2.2)	0.436	0.98	0.92	0.95
LI-RADS AF that favor Malignancy
Fat sparing	4 (8%)	6 (12%)	0.741	8 (17%)	12 (24%)	0.455	2 (4%)	4 (8%)	0.678	1 (2%)	4 (8%)	0.362	0.38	0.13	0.30
Iron sparing	1 (2%)	2 (4%)	0.999	2 (4%)	4 (8%)	0.678	0 (0%)	1 (2%)	0.999	1 (2%)	2 (4%)	0.999	0.42	-0.02	0.05
Blood products	2 (4%)	0 (0%)	0.237	15 (31%)	6 (12%)	0.027	3 (6%)	1 (2%)	0.352	7 (15%)	1 (2%)	0.028	0.14	0.47	0.21
Mild-moderate T2 hyperintensity	40 (80%)	46 (90%)	0.172	43 (86%)	45 (88%)	0.775	31 (62%)	45 (88%)	0.003	42 (84%)	43 (84%)	0.999	0.25	0.37	0.27
Restricted DWI	38 (75%)	29 (57%)	0.095	38 (75%)	29 (57%)	0.095	38 (75%)	29 (57%)	0.095	38 (75%)	29 (57%)	0.095	1.00	0.94	0.97
LI-RADS AF that favor HCC over non-HCC
Intralesional fat	25 (52%)	6 (12%)	<0.001	18 (38%)	5 (10%)	0.002	19 (40%)	2 (4%)	<0.001	13 (27%)	1 (2%)	<0.001	0.70	0.53	0.55
Mosaic architecture	33 (65%)	10 (20%)	<0.001	24 (47%)	7 (14%)	<0.001	19 (37%)	0 (0%)	<0.001	20 (39%)	17 (33%)	0.681	0.46	0.15	0.32
Nodule-in-nodule architecture	12 (36%)	3 (27%)	0.722	3 (12%)	0 (0%)	0.999	2 (11%)	0 (0%)	NA	6 (30%)	1 (6%)	0.104	0.36	0.41	0.38
Corona enhancement	1 (2%)	5 (10%)	0.205	4 (8%)	10 (20%)	0.148	1 (2%)	1 (2%)	0.999	9 (18%)	9 (18%)	0.999	−0.09	0.17	−0.00
Distinctive rim	5 (10%)	1 (2%)	0.205	2 (4%)	0 (0%)	0.495	2 (4%)	2 (4%)	0.999	5 (10%)	15 (29%)	0.023	−0.03	0.02	−0.02
LI-RADS AF that favor non-HCC over HCC
Marked restricted DWI	4 (31%)	14 (64%)	0.086	8 (62%)	18 (82%)	0.243	0 (0%)	4 (18%)	0.274	2 (15%)	1 (5%)	0.541	0.31	0.21	0.14
Target appearance on DWI	1 (8%)	5 (23%)	0.377	1 (8%)	4 (18%)	0.630	1 (8%)	12 (55%)	0.010	1 (8%)	3 (14%)	0.999	0.46	0.22	0.37
Liver surface retraction	8 (16%)	18 (35%)	0.04	8 (16%)	14 (27%)	0.228	5 (10%)	15 (29%)	0.023	2 (4%)	12 (24%)	0.008	0.35	0.58	0.47
Biliary obstruction	0 (0%)	7 (14%)	0.013	0 (0%)	3 (6%)	0.243	1 (2%)	8 (16%)	0.031	3 (6%)	8 (16%)	0.200	0.58	0.34	0.46
Peripheral APHE	7 (14%)	31 (62%)	<0.001	5 (10%)	21 (42%)	<0.001	7 (14%)	32 (64%)	<0.001	6 (12%)	20 (40%)	0.001	0.51	0.44	0.52
Progressive central enhancement	12 (24%)	42 (82%)	<0.001	13 (25%)	34 (67%)	<0.001	7 (14%)	38 (75%)	<0.001	12 (24%)	33 (65%)	< 0.001	0.47	0.52	0.51
Peripheral washout	2 (4%)	1 (2%)	0.999	0 (0%)	5 (10%)	0.056	3 (6%)	7 (14%)	0.318	0 (0%)	2 (4%)	0.495	−0.04	−0.04	0.06
Final Diagnosis													0.45	0.36	0.39
LR-3	0 (0%)	0 (0%)	<0.001	0 (0%)	3 (6%)	<0.001	0 (0%)	0 (0%)	<0.001	1 (2%)	0 (0%)
LR-4	2 (4%)	2 (4%)		3 (6%)	2 (4%)		0 (0%)	1 (2%)		8 (16%)	5 (10%)
LR-5	30 (59%)	2 (4%)		22 (43%)	5 (10%)		36 (71%)	5 (10%)		32 (63%)	8 (16%)
LR-5V	3 (6%)	2 (4%)		14 (27%)	2 (4%)		2 (4%)	1 (2%)		1 (2%)	0 (0%)
LR-M	16 (31%)	45 (88%)		12 (24%)	39 (76%)		13 (25%)	44 (86%)		9 (18%)	38 (75%)
LR-M vs. LR-non-M												<0.001	0.49	0.57	0.53

AR all readers, AF ancillary features, JR junior reader, SR senior reader, κ kappa statistic